Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: MP stock price vs AVTX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AVTX's multiple
Needs AVTX P/S.
Implied fair value · at MP's multiple
Needs MP P/S.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
11 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
MP Materials Corp. / DE · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
AVALO THERAPEUTICS, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
ALBEMARLE CORP
MP vs ALB
SOUTHERN COPPER CORP/
MP vs SCCO
Alcoa Corp
MP vs AA
KAISER ALUMINUM CORP
MP vs KALU
CytomX Therapeutics, Inc.
MP vs CTMX
IDEAYA Biosciences, Inc.
MP vs IDYA
Ocugen, Inc.
MP vs OCGN
CLOVER HEALTH INVESTMENTS, CORP. /DE
MP vs CLOV
Citius Pharmaceuticals, Inc.
MP vs CTXR
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe MP can sustain 10.1% revenue growth while improving margins from -66.6% operating margin and reducing net debt/EBITDA from 11.4x, then MP can justify its current range; otherwise, the relative valuation case is not strong enough to support the extreme implied upside.
On a headline basis, MP trades at 57.3x P/S versus AVTX at 12482.1x P/S, which makes MP look far cheaper than AVTX. However, the implied price of $15768.19 versus MP’s current price of $72.19 reflects an extreme model-driven upside that is not credible given the underlying revenue and margin profile.
Supporting Metrics
